[Inhalational antibacterial therapy for an exacerbation of chronic obstructive pulmonary disease].
The clinical efficiency of inhalational antibacterial therapy for Stage II chronic obstructive pulmonary disease (COPD) was evaluated in 100 patients who had been randomized to an inhalational fusafungine group (n = 50) and a systemic (per os or parenteral) antibiotics group (n = 50). Inhalational antibacterial therapy for exacerbations of Stage II COPD was found to be as effective as systemic use of antibiotics. Moreover, side effects of inhalational therapy were much less pronounced.